Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study

Lin, Caijin; Wu, Jiayi; Ding, Shuning; Goh, Chihwan; Andriani, Lisa; Shen, Kunwei; Zhu, Li

doi:10.4143/crt.2019.210

Cited by 18 publications

(20 citation statements)

References 30 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, subsequent subgroup analyses revealed that a prior cancer history could impair the survival of patients only when the interval time was less than two year. This time-frame finding was different from the study by Lin et al that demonstrated no survival detriment in patients with advanced breast cancer who had prior cancer outside the timeframe of 4 years [ 17 ].…”

Section: Discussioncontrasting

confidence: 92%

“…We found that approximately 4.5 % of patients had exactly one non-prostate prior cancer before the diagnosis of APC. This proportion was similar to advanced breast cancer but lower than advanced lung cancer [ 6 , 17 ]. Besides, similar to studies reported by Bluethmann et al [ 16 ] and Murphy et al [ 18 ], our study suggested that the elderly patients were more likely to have a history of prior cancer than the younger patients.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

Chen

Diao

et al. 2021

BMC Urol

View full text Add to dashboard Cite

Background A history of prior cancer commonly results in exclusion from cancer clinical trials. However, whether a prior cancer history has an adversely impact on clinical outcomes for patients with advanced prostate cancer (APC) remains largely unknown. We therefore aimed to investigate the impact of prior cancer history on these patients. Methods We identified patients with advanced prostate cancer diagnosed from 2004 to 2010 in the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was used to balance baseline characteristics. Kaplan–Meier method and the Cox proportional hazard model were utilized for survival analysis. Results A total of 19,772 eligible APC patients were included, of whom 887 (4.5 %) had a history of prior cancer. Urinary bladder (19 %), colon and cecum (16 %), melanoma of the skin (9 %) malignancies, and non-hodgkin lymphoma (9 %) were the most common types of prior cancer. Patients with a history of prior cancer had slightly inferior overall survival (OS) (AHR = 1.13; 95 % CI [1.02–1.26]; P = 0.017) as compared with that of patients without a prior cancer diagnosis. Subgroup analysis further indicated that a history of prior cancer didn’t adversely impact patients’ clinical outcomes, except in patients with a prior cancer diagnosed within 2 years, at advanced stage, or originating from specific sites, including bladder, colon and cecum, or lung and bronchus, or prior chronic lymphocytic leukemia. Conclusions A large proportion of APC patients with a prior cancer history had non-inferior survival to that of patients without a prior cancer diagnosis. These patients may be candidates for relevant cancer trials.

show abstract

Section: Discussioncontrasting

confidence: 92%

Section: Discussionmentioning

confidence: 95%

Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

Chen

Diao

et al. 2021

BMC Urol

View full text Add to dashboard Cite

show abstract

“…The high prevalence of a cancer history among individuals with a new cancer diagnosis may have important implications for the delivery of cancer treatment and survivorship care. Some reports, including those conducted using SEER data, have documented inferior overall survival among patients with certain cancer types, including breast, prostate, colorectal, uterine, thyroid, melanoma, and bladder, who have a prior cancer diagnosis compared to those without, even after accounting for demographic and tumor characteristics 2‐5 . For patients with these cancer types, prior cancer history may therefore influence decisions surrounding treatment for the newly diagnosed cancer.…”

Section: Discussionmentioning

confidence: 99%

“…An increase in the prevalence of the second or later cancer diagnoses may be consequential for several reasons. Some studies have suggested that, for certain cancer types, overall survival may be significantly lower for patients whose diagnosis is a second‐ or higher‐order primary, relative to those with a first primary cancer diagnosis 2‐5 . As a result, patients with a second or later primary cancer are often excluded from cancer clinical trials on the basis of their cancer history 6 .…”

Section: Introductionmentioning

confidence: 99%

Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers

Anderson

Mayer

Nichols

2021

Cancer

View full text Add to dashboard Cite

BACKGROUND Improvements in cancer survival mean that an increasing number of survivors may live long enough beyond their initial cancer to be diagnosed with additional independent primary cancers. The proportion of newly diagnosed cancers that are second‐ or higher‐order primaries and how this proportion has changed over the past several decades were examined. METHODS Data from the Surveillance, Epidemiology, and End Results (SEER) program were used to identify incident malignant primaries diagnosed between 1975 and 2017. Using the SEER sequence number, the authors tabulated the proportion of all cancers in each calendar year that were second‐ or higher‐order primaries. The average annual percent change (AAPC) was then calculated to assess how this proportion has changed over time. RESULTS Analyses included nearly 4.9 million incident cancers diagnosed during 1975‐2017. The proportion of all cancers that were second‐ or higher‐order increased steadily from 9.77% during 1975‐1984 to 21.03% during 2015‐2017, reflecting an AAPC of 2.41% (95% CI, 2.16%‐2.65%). In 2015‐2017, second‐ or higher‐order cancers were most prevalent among cancers of the bladder (28.79%), followed by lung and bronchus (28.07%), melanoma (27.88%), and leukemia (26.10%). The highest AAPCs over the study period were observed for melanoma (4.05%), leukemia (3.51%), and lung and bronchus (3.36%). CONCLUSIONS The proportion of newly diagnosed cancers that are second‐ or higher‐order has grown rapidly over the past several decades and currently exceeds 20%. Continued monitoring of second and later primaries will be critical for anticipating the future impact on cancer treatment and survivorship care.

show abstract

“…A SPM is defined as a cancer which arises independently in a new organ or tissue at least 2 months after the diagnosis of the prior primary cancer. Over 10% of younger adult cancer patients and around 25% of older adult cancer patients have been diagnosed with a SPM [9,10]. It has been reported to be associated with genetic susceptibility [11,12], the carcinogenic AGING adverse effects of cancer treatment [13], and behavioral risk factors such as smoking and alcohol intake [14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Risk of breast cancer-related death in women with a prior cancer

Yang

et al. 2020

Aging

View full text Add to dashboard Cite

The overall risk of developing a second primary cancer is increasing. The purpose of this study was to analyze the survival of patients with breast cancer diagnosed after a prior cancer and identify risk factors of breast cancer death in this population. Using the SEER database, we identified 1,310 woman diagnosed with breast cancer between 2010 and 2015 after a prior cancer as the primary cohort. Clinicopathological characteristics were compared using the Student t-test and chi-square test. Fine and Gray's regression was used to evaluate the effect of treatments on breast cancer death. After propensity score matching (PSM), 9,845 pairs of patients with breast cancer as the prior or second cancer diagnosed between 2010 and 2011 were included as a second cohort. PSM-adjusted Kaplan-Meier and Cox hazards models were used to evaluate the impact of prior cancer on survival. The results showed that survivors of gynecologic cancers (e.g., ovarian cancer) had a higher risk of developing breast cancer than survivors of gastrointestinal and urinary tract cancers. More patients died of breast cancer than of prior urinary cancer (53.3% vs. 40%, P < 0.05) and melanoma (66.7% vs. 33.3%, P < 0.05). The ratio of breast cancer deaths to prior cancer deaths was significantly higher in patients with diagnoses interval ≥ 3 years than in those with the interval < 3 years (2.67 vs. 0.69, P < 0.001). Breast cancer-specific survival and overall survival rates were significantly lower in women with breast cancer as the second primary cancer than in those with breast cancer as the prior cancer, especially among hormone receptor-positive women. However, breast cancer treatment decreased the risk of breast cancer -specific death (hazard ratio = 0.695, 95% confidence interval: 0.586-0.725, P < 0.001). Breast cancer patients with prior cancers must be carefully considered for clinical trials.

show abstract

Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study

Cited by 18 publications

References 30 publications

Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers

Risk of breast cancer-related death in women with a prior cancer

Contact Info

Product

Resources

About